Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Anktiva Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.684

    Nogapendekin Alfa Inbakicept-pmln (Anktiva)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.684 alerts

    Get alerted when Policy CP.PHAR.684 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity requirements for Anktiva administered with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer, including initial and continued therapy, dosing, documentation, and coding.

    Policy Summary
    PayerAmbetter Nevada
    PolicyNogapendekin Alfa Inbakicept-pmln (Anktiva)
    Policy CodePolicy CP.PHAR.684
    Change TypeModified
    Effective DateSep 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit provider attestation that Adstiladrin was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code J9028 was added for injection of nogapendekin alfa inbakicept-pmln for intravesical use, billed per 1 microgram.

    HCPCS codes J9999 and C9399 were removed from the policy coding references.

    The 3Q 2025 annual review recorded no significant changes and updated references while removing irrelevant drugs from the therapeutic alternatives appendix.

    An off-label indication was added for Ta/T1 high-grade disease without carcinoma in situ under NCCN guidance.

    The policy added an option for treatment to be prescribed by or provided in consultation with a urologist.

    The policy added a requirement that the member is not a candidate for cystectomy.

    The policy added provider attestation that Adstiladrin therapy was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.

    The initial approval duration was extended from 6 months to 12 months.

    The covered disease scope was updated for the FDA label expansion to include BCG-unresponsive non-muscle-invasive bladder cancer without carcinoma in situ.

    The ICHRA line of business was added during the 3Q 2026 annual review.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    400 mcgMaximum Anktiva dose per week
    37 monthsMaximum total treatment duration
    12 monthsApproval duration
    18 yearsMinimum age
    J9028HCPCS code
    BCG-unresponsive NMIBCCovered disease population

    Coverage Criteria

    Initial Therapy: BCG-Unresponsive NMIBC

    Covered for initial therapy when ALL of the following are met:

    ALL of the following

    • ONE of the following diagnoses

      • Carcinoma in situ (CIS) only.
      • Ta/T1 high-grade disease with concomitant CIS.
      • Ta/T1 high-grade disease without CIS.
    • Prescribed by or in consultation with an oncologist or urologist.
    • Member is age 18 years or older.>= 18 years
    • Member is refractory to BCG treatment. Prior authorization may be required for BCG immunotherapy.
    • Member is not a candidate for cystectomy.
    • Provider attests that Adstiladrin therapy has been considered and not recommended, and submits clinical rationale supporting use of Anktiva over Adstiladrin.
    • Anktiva is prescribed in combination with BCG.

    Continued Therapy: BCG-Unresponsive NMIBC

    Covered for continued therapy when ALL of the following are met:

    ALL of the following

    • Member is currently receiving the medication through the Centene benefit, or documentation supports that the member is currently receiving Anktiva for a covered indication and has received it for at least 30 days.>= 30 days
    • Member is responding positively to therapy, as evidenced by lack of disease recurrence or progression.
    • Total treatment duration does not exceed 37 months.<= 37 months
    • For a dose-increase request, ONE of the following

    Other Diagnoses and Indications

    For other diagnoses or indications, coverage follows criterion 1 OR criterion 2 below:

    ONE of the following

    • The drug has undergone a label change within the last 6 months—such as a newly approved indication, age expansion, or new dosing regimen—that is not yet reflected in this policy. Refer to the applicable no-coverage or non-formulary policy based on formulary or PDL status and line of business.
    • The requested use—including diagnosis, age, or dosing regimen—is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized, and criterion 1 does not apply. Refer to the applicable off-label use policy for the line of business.

    Initial Therapy Requirements

    Initial authorization also requires the prescribed regimen and request to satisfy ALL of the following requirements:

    ALL of the following

    • ONE of the following dose or evidence requirements

      • Dose does not exceed 400 mcg (1 vial) per week.<= 400 mcg (1 vial) per week
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.
    • The prescribed regimen is FDA-approved or recommended by NCCN.
    • Initial approval duration is 12 months.12 months

    Covered Indications

    Covered disease populations include ALL of the following applicable elements:

    ALL of the following

    • The member has BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
    • The disease is characterized by ONE of the following

      • CIS only.
      • Ta/T1 high-grade disease with concomitant CIS.
      • Ta/T1 high-grade disease without CIS, including BCG-unresponsive NMIBC without CIS (high-grade papillary-only tumors).

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy—CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid—or according to applicable evidence of coverage documents.

    Coding and Quantity Parameters

    Referenced HCPCS CodeHCPCS
    J9028Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
    Referenced HCPCS CodeHCPCS
    J9028Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
    Anktiva dose
    Maximum weekly dose400 mcg per week
    Vial quantity1 vial
    Off-label exceptionA higher or otherwise off-label dose may be considered when supported by practice guidelines or peer-reviewed literature for the relevant use; supporting evidence is required.
    Total treatment duration
    Maximum total treatment duration37 months
    Induction schedule400 mcg administered intravesically with BCG once weekly for 6 weeks

    Provider Requirements and Denial Risks

    Prior Authorization

    Anktiva Prior Authorization

    Anktiva requires prior authorization when applicable. Initial approval may be granted for up to 12 months when all policy criteria are met.

    • Initial approval duration: 12 months.
    • Continued therapy approval duration: 12 months.
    Prior Authorization

    Verify BCG Authorization

    BCG immunotherapy may require prior authorization. Verify benefit-specific requirements before initiating or requesting Anktiva, which must be prescribed in combination with BCG.

    • BCG is listed as a therapeutic alternative and may not be formulary for every line of business.
    • BCG dosing listed in the policy is 1 to 8 × 108 CFU intravesically once weekly for 6 weeks.

    Drug and Policy Background

    Nogapendekin alfa inbakicept-pmln (Anktiva) is an interleukin-15 receptor agonist. The FDA indication is for use in combination with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer, including carcinoma in situ and high-grade Ta/T1 disease patterns. Under this policy, treatment is administered intravesically with BCG, and the member must not be a candidate for cystectomy.

    Definitions and Abbreviations

    BCG
    AbbreviationBCG
    Full termBacillus Calmette-Guérin
    Policy useAnktiva is prescribed and administered intravesically in combination with BCG
    CIS
    AbbreviationCIS
    Full termCarcinoma in situ
    Covered disease patternCIS alone is one qualifying diagnosis for initial therapy

    Initial Therapy

    Initial Anktiva Therapy Criteria

    Initial therapy is covered when ALL of the following are met.

    Initial Anktiva therapy

    • Qualifying diagnosis

      • Diagnosis is carcinoma in situ (CIS) only.
      • Diagnosis is Ta/T1 high-grade disease with concomitant CIS.
      • Diagnosis is Ta/T1 high-grade disease without CIS.
    • Clinical and prescribing requirements

      • Anktiva is prescribed by or in consultation with an oncologist or urologist.

    Continued Therapy

    Continued Anktiva Therapy

    Continued therapy is covered when ALL of the following are met.

    Continuation criteria

    • Current treatment status

      • Member is currently receiving Anktiva through the Centene benefit.
      • Documentation supports that the member is currently receiving Anktiva for a covered indication and has received the medication for at least 30 days.At least 30 days
    • Response and duration

      • Member is responding positively to therapy, as evidenced by lack of disease recurrence or progression.

    Step Therapy Requirements

    StepRequirementDocumentation
    1
    Before Anktiva approval
    Provider attestation that Adstiladrin therapy has been considered and not recommended, with clinical rationale supporting use of Anktiva over Adstiladrin.
    StepRequirementTherapeutic alternative and regimen
    2
    Anktiva must be prescribed in combination with BCG.
    Bacillus Calmette-Guérin (TICE BCG) is the therapeutic alternative and is administered intravesically once weekly for 6 weeks.
    StepRequirementDocumentation
    1
    Before Anktiva approval
    Provider attestation that Adstiladrin therapy has been considered and is not recommended, with clinical rationale supporting Anktiva over Adstiladrin.

    Quantity and Duration Limits

    Anktiva quantity limits
    Weekly dose400 mcg per week
    Vial quantity1 vial
    Maximum total treatment duration37 months
    Anktiva dose increase
    Dose-increase limit400 mcg per week
    Vial quantity1 vial
    Maximum number of dosesUp to a total of 24 doses

    Site and Route of Administration

    Billing Rule

    Administer Anktiva with BCG in the office

    Anktiva is administered intravesically with BCG in the office setting.

    Policy Summary
    PayerAmbetter Nevada
    PolicyNogapendekin Alfa Inbakicept-pmln (Anktiva)
    Policy CodePolicy CP.PHAR.684
    Change TypeModified
    Effective DateSep 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit provider attestation that Adstiladrin was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity ParametersProvider Requirements and Denial RisksDrug and Policy BackgroundDefinitions and AbbreviationsInitial TherapyContinued TherapyStep Therapy RequirementsQuantity and Duration LimitsSite and Route of Administration
    The new dose does not exceed 400 mcg (1 vial) per week for up to a total of 24 doses.
    <= 400 mcg (1 vial) per week; up to 24 doses
  1. The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.
  2. Maintenance schedule
    400 mcg administered with BCG once weekly for 3 weeks at months 4, 7, 10, 13, and 19, with possible additional courses at months 25, 31, and 37
    Continued-therapy dose increase
    Dose-increase limitNew dose must not exceed 400 mcg per week
    Vial quantity1 vial
    Maximum number of dosesUp to a total of 24 doses
    Evidence exceptionA different dose may be considered when supported by practice guidelines or peer-reviewed literature for the relevant off-label use; supporting evidence is required.
    Minimum age
    Minimum age18 years
    Eligibility wordingMember must be at least 18 years old
    Applicable therapyCovered initial Anktiva therapy for qualifying BCG-refractory non-muscle-invasive bladder cancer
    Adequate initial BCG induction
    Minimum completed induction dosesAt least 5 of 6 doses
    Maintenance-course pathwayAt least 2 of 3 maintenance doses after the initial induction course
    Second-induction pathwayAt least 2 of 6 doses of a second induction course after the initial induction course
    Documentation Required

    Document the Applicable NMIBC Population

    Submit clinical documentation demonstrating that the member meets the applicable criteria for BCG-unresponsive non-muscle-invasive bladder cancer, including the documented diagnosis and relevant treatment history.

    • Document the applicable NMIBC disease presentation and BCG-refractory or BCG-unresponsive status.
    • Include records supporting the requested indication and treatment plan.
    Step Therapy

    Consider Adstiladrin First

    Before selecting Anktiva, consider Adstiladrin first. The provider must attest that Adstiladrin therapy was considered and not recommended, and submit the clinical rationale supporting Anktiva over Adstiladrin.

    • Include the attestation in the authorization request.
    • Explain why Adstiladrin is not recommended for this member and why Anktiva is clinically appropriate.

    Unsupported block type: prior_auth

    Documentation Required

    Adstiladrin Attestation and Rationale

    For every request, document that Adstiladrin was considered and not recommended, with an individualized clinical rationale for choosing Anktiva instead. This attestation remains relevant for initial and applicable updated authorization requests.

    • Do not submit a generic statement alone; provide member-specific clinical reasoning.
    • Update the attestation and rationale when circumstances or the requested therapy change.
    Documentation Required

    Submit Clinical Documentation

    Submit office chart notes, laboratory results, and other clinical records supporting that the member has met all approval criteria.

    • Documentation must support the diagnosis, prescriber involvement, treatment history, cystectomy status, regimen, and requested duration or dose.

    Unsupported block type: documentation

    Documentation Required

    Document the Treatment Selection

    The provider must document consideration of Adstiladrin and provide a clinical rationale for selecting Anktiva over that therapy before requesting approval.

    • Attestation: Adstiladrin was considered and not recommended.
    • Rationale: explain why Anktiva is preferred for this member.
    Documentation Required

    Keep the Attestation Current

    Maintain an updated Adstiladrin attestation and clinical rationale with the authorization record when submitting a new, renewed, or modified request.

    • The rationale should remain specific to the member’s disease characteristics and treatment history.
    • Resubmit supporting documentation when the requested regimen or clinical circumstances change.
    Documentation Required

    Document Cystectomy Status

    Document that the member is not a candidate for cystectomy and include the relevant urologic evaluation or consultation supporting that determination.

    • Anktiva criteria require that the member is not a candidate for cystectomy.
    • The prescription must be by or in consultation with an oncologist or urologist.
    Denial Risk

    Initial Approval Denial Risks

    Initial approval may be denied when any required criterion is not met or when the submitted documentation does not support the requested therapy.

    • The diagnosis, specialist involvement, age, BCG-refractory status, cystectomy status, Adstiladrin consideration, BCG combination, and dose requirements must be supported.
    • Requests that do not meet the FDA-approved or NCCN-recommended regimen requirement may be denied unless applicable dose-supporting evidence is submitted.
    Denial Risk

    Continuation Approval Denial Risks

    Continuation requests may be denied when the member is not actively receiving covered Anktiva, has not received therapy for at least 30 days, is not responding, exceeds the 37-month total treatment limit, or fails dose-increase requirements.

    • Document positive response, demonstrated by lack of disease recurrence or progression.
    • For a dose increase, submit the required dose limit or supporting guidelines or peer-reviewed literature.
    Denial Risk

    Unauthorized Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient efficacy and safety documentation is submitted under the applicable off-label use policy or evidence of coverage.

    • For Ambetter Nevada marketplace/ICHRA business, the source identifies HIM.PA.154 as the applicable off-label policy.
    • Do not assume an unaddressed indication is covered under this Anktiva policy.
    Denial Risk

    Meet Clinical Authorization Requirements

    Requests may be denied when the submitted clinical documentation does not establish that the applicable authorization requirements are satisfied, including the updated NMIBC indication and supporting treatment rationale.

    • Provide records supporting BCG-unresponsive NMIBC, cystectomy status, Adstiladrin consideration, BCG combination therapy, and the requested dose.
    • Ensure the authorization submission is consistent with the FDA-approved or NCCN-recommended regimen.
    FDA
    AbbreviationFDA
    Full termFood and Drug Administration
    Regimen standardThe prescribed regimen must be FDA-approved or recommended by NCCN
    IL
    AbbreviationIL
    Full termInterleukin
    Glossary locationListed in the policy’s abbreviation and acronym key
    NMIBC
    AbbreviationNMIBC
    Full termNon-muscle invasive bladder cancer
    Policy applicationThe policy addresses Anktiva treatment for NMIBC
    NCCN
    AbbreviationNCCN
    Full termNational Comprehensive Cancer Network
    Policy useThe prescribed regimen must be FDA-approved or recommended by NCCN
    BCG-refractory or BCG-unresponsive
    CIS disease patternPersistent or recurrent CIS alone
    Papillary disease patternRecurrent Ta/T1 disease within 12 months after completion of adequate BCG therapy
    Adequate BCG therapyAt least 5 of 6 initial induction doses plus either at least 2 of 3 maintenance doses or at least 2 of 6 doses of a second induction course
    BCG-unresponsive NMIBC without CIS
    Disease typeBCG-unresponsive non-muscle-invasive bladder cancer
    CIS statusWithout carcinoma in situ
    Tumor descriptionHigh-grade papillary-only tumors
  3. Member is at least 18 years old.≥ 18 years
  4. Member is refractory to BCG treatment.
  5. Member is not a candidate for cystectomy.
  6. Provider attests that Adstiladrin therapy was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.
  7. Anktiva is prescribed in combination with BCG.
  8. Dose and regimen requirement

    • Dose does not exceed 400 mcg (1 vial) per week.400 mcg (1 vial) per week
    • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

      The prescriber must submit supporting evidence. The prescribed regimen must be FDA-approved or recommended by NCCN.

  9. Initial Therapy

    Initial approval is available for covered BCG-unresponsive NMIBC populations when ALL of the following updated authorization conditions are met.

    Initial Anktiva authorization

    • Use is for a covered BCG-unresponsive non-muscle-invasive bladder cancer indication, including an applicable covered population without carcinoma in situ.
    • Member is not a candidate for cystectomy.
    • Treatment is prescribed by or provided in consultation with a urologist.
    • Provider attests that Adstiladrin therapy was considered and not recommended, with clinical rationale supporting Anktiva over Adstiladrin.
  10. Total treatment duration does not exceed 37 months.Maximum 37 months
  11. Dose increase requirement

    • New dose does not exceed 400 mcg (1 vial) per week for up to a total of 24 doses.400 mcg (1 vial) per week; up to 24 doses
    • New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

      The prescriber must submit supporting evidence. The prescribed regimen must be FDA-approved or recommended by NCCN.